^
Association details:
| Biomarker: | PTPN11 negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + gemcitabine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non-small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy
Excerpt:
In contrast, patients with negative SHP2 expression had a higher survival rate (median overall survival 68 vs. 24 months, P=0.003). Cox multivariate regression analysis showed that SHP2 was an independent indicator for overall survival (P=0.009)….The present study suggested that NSCLC patients with negative SHP2 expression could benefit from gemcitabine plus carboplatin chemotherapy...
DOI:
10.21037/apm-20-43
